GenSight Biologics Announces its 2024 Financial Calendar
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
GenSight Biologics Announces Initial Results from New Meta-Analyses
GenSight Announces Update on Data from Early Access Programs of LUMEVOQ
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology